A method for preparing recombinant feline relaxinogen protein, feline relaxin polyclonal antibody, and monoclonal antibody.
By preparing recombinant feline relaxinogen protein and polyclonal and monoclonal antibodies, the problems of low protein content and insufficient antibody specificity in feline relaxin detection have been solved, achieving highly specific and sensitive feline pregnancy detection.
Patent Information
- Application Number
- CN202611597757.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-15
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies have low levels of natural cat relaxin protein, making it difficult to obtain in large quantities. Commercial antibodies lack specificity, resulting in limited detection sensitivity and specificity, which makes it difficult to meet the needs for rapid detection of blood and urine samples.
Recombinant feline relaxinogen protein and polyclonal and monoclonal antibodies against feline relaxin were prepared. Highly specific and high-affinity antibodies were obtained by constructing expression plasmids, purifying proteins, immunizing animals, cell fusion, and screening hybridoma cells.
It achieves highly specific and sensitive detection of feline relaxin, suitable for rapid detection in blood, plasma, serum, and urine samples, improving the accuracy and sensitivity of feline pregnancy detection.
Smart Images

Figure CN123106876A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biological immunology, specifically a method for preparing recombinant feline relaxinogen protein and feline relaxin polyclonal and monoclonal antibodies. Background Technology
[0002] Currently, feline pregnancy diagnosis mainly relies on methods such as ultrasound examination, palpation, and hormone testing. Relaxin is a pregnancy-related protein hormone produced by placental tissue during feline pregnancy and released into the blood and urine as pregnancy progresses. Compared to traditional progesterone testing methods, relaxin has better pregnancy specificity and can serve as an important biomarker for early detection of pregnancy in cats.
[0003] Currently available cat relaxin testing products on the market have the following problems:
[0004] First, cat relaxin has a low content of natural protein, making it difficult to obtain in large quantities.
[0005] Second, some commercial antibodies lack specificity, resulting in limited detection sensitivity and specificity;
[0006] Third, there is a lack of high-affinity monoclonal antibodies developed targeting the structural characteristics of feline relaxin;
[0007] Fourth, it is difficult to meet the demand for rapid testing of blood and urine samples.
[0008] In summary, this invention provides a method for preparing recombinant feline relaxinogen protein, as well as feline relaxin polyclonal and monoclonal antibodies, to solve the above-mentioned problems. Summary of the Invention
[0009] To address the aforementioned technical problems, this invention provides a method for preparing recombinant feline relaxinogen protein, feline relaxin polyclonal antibody, and monoclonal antibody, thereby resolving the difficulties in meeting the rapid detection requirements of blood and urine samples in the prior art.
[0010] A method for preparing recombinant feline relaxinogen protein, feline relaxin polyclonal antibody, and monoclonal antibody includes the following steps:
[0011] Step 1: Construct an expression plasmid containing the coding sequence of cat relaxin, transfer the expression plasmid into host cells, transform it into E. coli by heat shock at 42℃, and obtain positive engineered bacteria through antibiotic selection;
[0012] Step 2: Pick a single colony from the above steps and inoculate it into 10 mL of LB liquid medium. Incubate overnight at 37°C with shaking at 250 rpm. Centrifuge to collect the bacterial cells and sonicate to disrupt them. After disruption, centrifuge to collect the supernatant and precipitate. Dissolve the precipitate with high-concentration urea and centrifuge to collect the dissolved supernatant.
[0013] Step 3: Obtain purified protein using affinity chromatography, ion exchange chromatography, or molecular sieve chromatography. The purified recombinant protein is then analyzed for protein content using SDS-PAGE, Western Blot, or ELISA.
[0014] Step 4: Using the recombinant feline relaxin proton protein prepared in Step 3 as an immunogen, it is mixed and emulsified with Freund's complete adjuvant (for initial immunization) or Freund's incomplete adjuvant (for booster immunization) in a 1:1 ratio to prepare a water-in-oil emulsion.
[0015] Step 5: Select healthy adult experimental animals for immunization, perform multiple booster immunizations, collect serum, and obtain feline relaxin polyclonal antibodies using Protein A / G or antigen affinity purification.
[0016] Step Six: Using the recombinant cat relaxin protein prepared in Step Five as an immunogen, prepare the immunogen and immunize the animals, isolate immune spleen cells, perform cell fusion, and screen and clone hybridoma cells.
[0017] Step 7: Subcloning is performed on the positive wells from Step 6 using the limiting dilution method. Then, the antibody-positive cells that are growing as monoclonal cells are recloned and cultured for testing until a monoclonal hybridoma cell line that can stably secrete specific antibodies is obtained. Monoclonal antibodies are then prepared, and finally, the monoclonal antibodies are purified and screened to obtain high-affinity and high-specificity cat relaxin monoclonal antibodies.
[0018] Furthermore, the host cell is preferably a competent Escherichia coli cell, including but not limited to strains such as BL21(DE3) and Rosetta(de3), and the resistance screening uses kanamycin, ampicillin, etc.
[0019] Furthermore, in step two, the bacterial culture is transferred to 1000 mL LB liquid medium at a ratio of 1%, and cultured at 37°C with shaking at 250 rpm until the logarithmic growth phase, where the OD600 is 0.6–0.8. Then, 0.1–1 mM isopropyl-β-D-thiogalactoside (IPTG) is added as an inducer, and the culture is induced at 16–25°C for 4–16 h.
[0020] Furthermore, in step three, the supernatant after crushing and the supernatant after precipitate dissolution are loaded onto a pre-equilibrated nickel column. After loading, the column is washed with washing buffer for 8 to 10 column volumes. The target protein is eluted with elution buffer containing imidazole (20 to 500 mM), and different components are collected stepwise to complete the purification.
[0021] Furthermore, the experimental animals selected include rabbits, sheep, and mice. Immunization routes include multiple subcutaneous injections on the back, intramuscular injections, or subcutaneous injections in the groin. The immunization schedule involves booster immunizations 2-3 weeks after the initial immunization, for a total of 3-4 immunizations. Each immunization dose is 0.2-1.0 mg / animal. Serum is collected 7-10 days after the booster immunization, from the marginal ear vein or heart, and the supernatant is collected by centrifugation.
[0022] Furthermore, in step six, healthy adult Balb / c mice are immunized using methods, dosages, and procedures similar to those used in polyclonal antibody preparation. Three days after the final booster immunization, the mouse spleen is aseptically removed and a single-cell suspension is prepared using serum-free culture medium. Spleen cells and myeloma cells are fused at a ratio of 1:10 or 1:5 using polyethylene glycol (PEG). The fused cells are then screened using HAT selective medium. Seven to fourteen days post-fusion, positive hybridoma cell wells secreting anti-cat relaxin antibodies are selected using ELISA.
[0023] Furthermore, in step seven, the cells in the positive wells are aspirated, counted, and diluted with complete culture medium to 1000 cells / mL, 100 cells / mL, 50 cells / mL, 20 cells / mL, 10 cells / mL, and 5 cells / mL, and then cultured until visible cell clones grow before antibody detection is performed.
[0024] Furthermore, the preparation of the monoclonal antibody includes:
[0025] In vitro culture method: Hybridoma cells are cultured in cell culture flasks to expand their size, and the culture supernatant is collected;
[0026] Ascites preparation method: Hybridoma cells are injected into the peritoneal cavity of mice, and ascites is collected.
[0027] Furthermore, the monoclonal antibody was purified using Protein A / G affinity chromatography. The purity of the purified antibody was identified by SDS-PAGE, and its titer, affinity, and specificity were determined by ELISA. This allowed for the screening of high-affinity and high-specificity feline relaxin monoclonal antibodies.
[0028] Compared with the prior art, the present invention has the following beneficial effects:
[0029] This invention establishes a stable method for preparing recombinant feline relaxin antigen; obtains highly specific feline relaxin polyclonal antibodies; obtains feline relaxin monoclonal antibodies suitable for immunochromatographic detection; can be used for detection in blood, plasma, serum and urine samples; and can be used to develop rapid feline pregnancy detection reagents, improving detection sensitivity and accuracy. Attached Figure Description
[0030] Figure 1This is a flowchart of the method of the present invention. Detailed Implementation
[0031] The embodiments of the present invention will be described in further detail below with reference to the accompanying drawings and examples. The following examples are for illustrative purposes only and should not be construed as limiting the scope of the invention.
[0032] like Figure 1 As shown, this invention provides a method for preparing recombinant feline relaxinogen protein, feline relaxin polyclonal antibody, and monoclonal antibody, comprising the following steps:
[0033] Step 1: Construct an expression plasmid containing the coding sequence of cat relaxinogen, and transform the expression plasmid into host cells. The host cells are preferably competent Escherichia coli cells, including but not limited to strains such as BL21(DE3) and Rosetta(de3). Transform into Escherichia coli by heat shock at 42℃, and obtain positive engineered bacteria through resistance selection. The resistance selection uses kanamycin, ampicillin, etc.
[0034] The construction of the feline relaxinogen recombinant expression vector involves ligating the optimized feline relaxinogen gene into an expression vector. The expression vector is selected from pET series vectors (such as pET28a, pET32a), pGEX series vectors, or pMAL series vectors. Expression systems include, but are not limited to, E. coli expression systems, Pichia pastoris expression systems, and mammalian cell expression systems. Tag-based fusion expression methods are preferred, including but not limited to: His tag, GST tag, Fc fusion tag, and MBP tag. The expression vector also contains expression regulatory elements such as a promoter, ribosome binding site, and transcription terminator.
[0035] Step 2: Pick a single colony from the above steps and inoculate it into 10 mL of LB liquid medium. Incubate overnight at 37°C with shaking at 250 rpm. Transfer the bacterial culture to 1000 mL of LB liquid medium at a ratio of 1%, and incubate at 37°C with shaking at 250 rpm until the logarithmic growth phase is reached, with an OD600 of 0.6–0.8. Add 0.1–1 mM isopropyl-β-D-thiogalactoside (IPTG) as an inducer and induce at 16–25°C for 4–16 h. Collect the bacterial cells by centrifugation and sonicate them. After disruption, collect the supernatant and precipitate by centrifugation. Dissolve the precipitate with high-concentration urea and centrifuge to collect the dissolved supernatant.
[0036] Step 3: Obtain purified protein using affinity chromatography, ion exchange chromatography, or molecular sieve chromatography. Load the supernatant after lysis and the supernatant after dissolving the precipitate onto a pre-equilibrated nickel column. After loading, wash with washing buffer for 8-10 column volumes. Elute the target protein with elution buffer containing imidazole (20-500 mM) and collect different fractions stepwise to complete the purification. The purified recombinant protein is analyzed for protein content by SDS-PAGE, Western Blot, and ELISA.
[0037] Step 4: Using the recombinant feline relaxin proton protein prepared in Step 3 as an immunogen, it is mixed and emulsified with Freund's complete adjuvant (for initial immunization) or Freund's incomplete adjuvant (for booster immunization) in a 1:1 ratio to prepare a water-in-oil emulsion.
[0038] Step 5: Select healthy adult laboratory animals for immunization, with multiple booster immunizations. The immunization schedule is as follows: after the initial immunization, booster immunizations are performed at intervals of 2-3 weeks, for a total of 3-4 immunizations. The dose for each immunization is 0.2-1.0 mg / animal. Serum is collected 7-10 days after the booster immunization, from the marginal ear vein or heart. The supernatant is collected by centrifugation and is the serum. The feline relaxin polyclonal antibody is obtained by purification using Protein A / G or antigen affinity.
[0039] Among them, experimental animals include rabbits, sheep, and mice, and the immunization routes include multiple subcutaneous injections on the back, intramuscular injections, or subcutaneous injections in the groin.
[0040] Step Six: Using the recombinant feline relaxin protein prepared in Step Five as an immunogen, immunogen preparation and animal immunization were performed. Healthy adult Balb / c mice were selected for immunization. The immunization method, dosage, and procedure were similar to those for polyclonal antibody preparation. Immunized spleen cells were isolated. Three days after the final booster immunization, the mouse spleen was aseptically removed, and a single-cell suspension was prepared using serum-free culture medium for cell fusion. Spleen cells and myeloma cells were fused at a ratio of 1:10 or 1:5 using polyethylene glycol (PEG). The fused cells were screened and cultured in HAT selective medium. 7–14 days after fusion, positive hybridoma cell wells secreting anti-feline relaxin antibodies were screened using ELISA. Hybridoma cell screening and cloning were then performed.
[0041] Step 7: Subcloning is performed on the positive wells from Step 6 using the limiting dilution method. Cells from the positive wells are aspirated, counted, and diluted with complete culture medium to 1000 cells / mL, 100 cells / mL, 50 cells / mL, 20 cells / mL, 10 cells / mL, and 5 cells / mL. The cells are then cultured until visible cell clones are observed, and antibody detection is performed. Cells that are antibody positive and showing monoclonal growth are then recloned and cultured for further detection until a monoclonal hybridoma cell line that can stably secrete specific antibodies is obtained. Monoclonal antibodies are then prepared, purified, and screened to obtain high-affinity and high-specificity cat relaxin monoclonal antibodies.
[0042] The preparation of monoclonal antibodies includes:
[0043] In vitro culture method: Hybridoma cells are cultured in cell culture flasks to expand their size, and the culture supernatant is collected;
[0044] Ascites preparation method: Hybridoma cells are injected into the peritoneal cavity of mice, and ascites is collected.
[0045] The monoclonal antibodies were purified using Protein A / G affinity chromatography. The purity of the purified antibodies was determined by SDS-PAGE, and their titer, affinity, and specificity were measured by ELISA. This process resulted in the screening of high-affinity and high-specificity feline relaxin monoclonal antibodies.
[0046] The embodiments of the present invention are given for the purposes of illustration and description. Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of the present invention.
Claims
1. A method for preparing a feline relaxin prorecombinant protein and feline relaxin polyclonal and monoclonal antibodies, characterized by, Includes the following steps: Step 1: Construct an expression plasmid containing the coding sequence of cat relaxin, transfer the expression plasmid into host cells, transform it into E. coli by heat shock at 42℃, and obtain positive engineered bacteria through antibiotic selection; Step 2: Pick a single colony from the above steps and inoculate it into 10 mL of LB liquid medium. Incubate overnight at 37°C with shaking at 250 rpm. Centrifuge to collect the bacterial cells and sonicate to disrupt them. After disruption, centrifuge to collect the supernatant and precipitate. Dissolve the precipitate with high-concentration urea and centrifuge to collect the dissolved supernatant. Step 3: Obtain purified protein using affinity chromatography, ion exchange chromatography, or molecular sieve chromatography. The purified recombinant protein is then analyzed for protein content using SDS-PAGE, Western Blot, or ELISA. Step 4: Using the recombinant feline relaxin proton protein prepared in Step 3 as an immunogen, it is mixed and emulsified with Freund's complete adjuvant (for initial immunization) or Freund's incomplete adjuvant (for booster immunization) in a 1:1 ratio to prepare a water-in-oil emulsion. Step 5: Select healthy adult experimental animals for immunization, perform multiple booster immunizations, collect serum, and obtain feline relaxin polyclonal antibodies using Protein A / G or antigen affinity purification. Step Six: Using the recombinant cat relaxin protein prepared in Step Five as an immunogen, prepare the immunogen and immunize the animals, isolate immune spleen cells, perform cell fusion, and screen and clone hybridoma cells. Step 7: Subcloning is performed on the positive wells from Step 6 using the limiting dilution method. Then, the antibody-positive cells that are growing as monoclonal cells are recloned and cultured for testing until a monoclonal hybridoma cell line that can stably secrete specific antibodies is obtained. Monoclonal antibodies are then prepared, and finally, the monoclonal antibodies are purified and screened to obtain high-affinity and high-specificity cat relaxin monoclonal antibodies.
2. The method for preparing the recombinant feline relaxinogen protein, feline relaxin polyclonal antibody, and monoclonal antibody as described in claim 1, characterized in that, The host cell is preferably a competent Escherichia coli cell, including but not limited to strains such as BL21(DE3) and Rosetta(de3), and the resistance screening uses kanamycin, ampicillin, etc.
3. The method for preparing the recombinant feline relaxinogen protein, feline relaxin polyclonal antibody, and monoclonal antibody as described in claim 1, characterized in that, In step two, the bacterial culture is transferred to 1000 mL LB liquid medium at a ratio of 1%, and cultured at 37°C with shaking at 250 rpm until the logarithmic growth phase, where the OD600 is 0.6–0.
8. 0.1–1 mM isopropyl-β-D-thiogalactoside (IPTG) is added as an inducer, and the culture is induced at 16–25°C for 4–16 h.
4. The method for preparing the recombinant feline relaxinogen protein, feline relaxin polyclonal antibody, and monoclonal antibody as described in claim 1, characterized in that, In step three, the supernatant after crushing and the supernatant after dissolving the precipitate are loaded onto a pre-equilibrated nickel column. After loading, the column is washed with washing buffer for 8 to 10 column volumes. The target protein is eluted with elution buffer containing imidazole (20 to 500 mM), and different components are collected stepwise to complete the purification.
5. The method for preparing the recombinant feline relaxinogen protein, feline relaxin polyclonal antibody, and monoclonal antibody as described in claim 1, characterized in that, The experimental animals selected were rabbits, sheep, and mice. Immunization routes included multiple subcutaneous injections on the back, intramuscular injections, or subcutaneous injections in the groin. The immunization schedule consisted of 3-4 booster immunizations, administered 2-3 weeks after the initial immunization. The dose for each immunization was 0.2-1.0 mg per animal. Serum was collected 7-10 days after the booster immunization, from the marginal ear vein or heart, and the supernatant was collected by centrifugation.
6. The method for preparing the recombinant feline relaxinogen protein, feline relaxin polyclonal antibody, and monoclonal antibody as described in claim 1, characterized in that, In step six, healthy adult Balb / c mice were immunized using a method, dosage, and procedure similar to that used in polyclonal antibody preparation. Three days after the final booster immunization, the mouse spleens were aseptically removed and a single-cell suspension was prepared using serum-free culture medium. Spleen cells and myeloma cells were fused at a ratio of 1:10 or 1:5 using polyethylene glycol (PEG). The fused cells were then cultured in HAT selective medium for selection. Seven to 14 days post-fusion, ELISA was used to screen for positive hybridoma cell wells secreting anti-cat relaxin antibodies.
7. The method for preparing the recombinant feline relaxinogen protein, feline relaxin polyclonal antibody, and monoclonal antibody as described in claim 1, characterized in that, In step seven, the cells in the positive wells are aspirated, counted, and diluted with complete culture medium to 1000 cells / mL, 100 cells / mL, 50 cells / mL, 20 cells / mL, 10 cells / mL, and 5 cells / mL, and then cultured until visible cell clones grow before antibody detection.
8. The method for preparing the recombinant feline relaxinogen protein, feline relaxin polyclonal antibody, and monoclonal antibody as described in claim 1, characterized in that, The preparation of the monoclonal antibody includes: In vitro culture method: Hybridoma cells are cultured in cell culture flasks to expand their size, and the culture supernatant is collected; Ascites preparation method: Hybridoma cells are injected into the peritoneal cavity of mice, and ascites is collected.
9. The method for preparing the recombinant feline relaxinogen protein, feline relaxin polyclonal antibody, and monoclonal antibody as described in claim 1, characterized in that, Monoclonal antibodies were purified using Protein A / G affinity chromatography. The purity of the purified antibodies was determined by SDS-PAGE, and their titer, affinity, and specificity were measured by ELISA. This process allowed for the screening of high-affinity and high-specificity feline relaxin monoclonal antibodies.
